Search

News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.

Source: Oncological Treatment 15. 9. 2021

News Current Treatment Options for Refractory/Relapsed CLL

How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory disease.

Source: Chronic Lymphocytic Leukemia 8. 9. 2022

News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity

A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.

Source: Thyroid Disorders 16. 10. 2023

News Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins –⁠ A Systematic Review of the Literature

The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in patients with primary immunodeficiency (PID) who had not previously been treated with this modality. There was insufficient data available for such a defined population because SCIGs had typically been introduced into studies only after intravenously administered immunoglobulins (IVIG).

Source: Primary and Secondary Immunodeficiencies 1. 12. 2023

News Asthma is not a risk factor for a severe course of COVID-19

According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.

Source: Asthma under control 12. 6. 2020

News Through Obstacles to the Stars –⁠ Path to Developing a Healthy Gut Microbiota in Children: What Blocks It and What Helps?

The gut microbiota is acquired by an individual during the first 2 years of life. The main source is the mother’s microbiota. Obstacles to the formation of an adequate microbiota include inappropriate composition of the mother’s microbiota, absence of vaginal birth and breastfeeding, as well as artificial feeding and antibiotic treatment in the child. We provide a summary of current findings on the adverse effects of planned cesarean sections on the child’s microbiome, as recently published in Critical Reviews in Microbiology.

Source: GI, colic and microbiome 21. 4. 2020

Články časopisu Hereditary angioedema in gravidity

Author of the article: MUDr. Barbora Kuřecová, MUDr. Petr Janků, prof. MUDr. Jiří Litzman, CSc. Source: Praktická gynekologie | 2/2006 13. 4. 2006

News Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML

Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) –⁠ newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).

Source: Chronic Lymphocytic Leukemia 17. 2. 2022

News How and How the Czech National Hemophilia Program Benefits Professionals and Patients

The Czech National Hemophilia Program (ČNHP) has been an interdisciplinary initiative for many years, coordinating specialized care for both pediatric and adult patients with hemophilia and other congenital bleeding disorders in the Czech Republic. It was established on the platform of collaboration among experts from hematology centers that deal with this issue and is guided by the ČNHP Declaration, which is published on the association's website (see www.cnhp.cz).

Source: Von Willebrand Disease 25. 2. 2022

News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases

Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.

Source: Biological Treatment 26. 10. 2020

News Targeted Treatment of Metastatic Breast Cancer in the 2nd Line –⁠ Experiences from Practice

The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves dual blockade of the HER2 signaling pathway using trastuzumab and pertuzumab in combination with a taxane cytostatic. After the failure of this therapy, treatment with trastuzumab emtansine (T-DM1) is recommended. However, this recommendation is not supported by a prospectively designed controlled study examining the outcomes of this therapeutic sequence. Therefore, a group of Italian authors decided to publish the results of a patient cohort treated with this sequence in real clinical practice conditions.

Source: Breast Carcinoma 23. 11. 2020

News How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?

What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the patients' perspective, what do they fear, what approaches do they prefer, and why? Lozano et al. included a discussion on this topic in their review article for Expert Review of Hematology, which can be helpful in clinical practice for better understanding patients' needs and adjusting treatment algorithms.

Source: Immune Thrombocytopenia 21. 11. 2023

News Micronutrients in Parenteral Nutrition in Adult Patients –⁠ Current Issues and Consensus

Micronutrients are a key nutritional component, and this is also true for patients whose condition requires the administration of parenteral nutrition. An article published last year in the Journal of Parenteral and Enteral Nutrition summarizes the expert literature on this topic as well as current guidelines and addresses 14 clinically most relevant questions related to the importance, administration, and monitoring of micronutrients.

Source: Parenteral Nutrition 23. 11. 2020

News Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care

What is the importance of prophylaxis in 'non-severe' hemophilia A? Italian doctors have attempted to answer this question in their recent expert consensus.

Source: Hemophilia 4. 7. 2023

News Options for Preventing Enteral Nutrition Intolerance in Mechanically Ventilated Patients in the ICU

Standards of care for critically ill patients recommend enteral nutrition for those on mechanical ventilation. A recently published study addressed the question of how to identify patients at risk of enteral nutrition intolerance (ENI) and how to subsequently prevent this intolerance, which may be associated with worse clinical outcomes.

Source: Enteral Nutrition 12. 4. 2021